Join Growin Stock Community!

Immunic, inc.IMUX.US Overview

US StockHealthcare
(No presentation for IMUX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IMUX AI Insights

IMUX Overall Performance

IMUX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IMUX Recent Performance

1.96%

Immunic, inc.

0.05%

Avg of Sector

-0.31%

S&P500

IMUX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IMUX Key Information

IMUX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IMUX Profile

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Price of IMUX

IMUX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IMUX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.98
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
10.85
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.98
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
10.85
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IMUX's latest earnings report released?

    The most recent financial report for Immunic, inc. (IMUX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IMUX's short-term business performance and financial health. For the latest updates on IMUX's earnings releases, visit this page regularly.

  • How much cash does IMUX have?

    At the end of the period, Immunic, inc. (IMUX) held Total Cash and Cash Equivalents of 15.48M, accounting for 0.64 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is IMUX's EPS continuing to grow?

    According to the past four quarterly reports, Immunic, inc. (IMUX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.07. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IMUX?

    Immunic, inc. (IMUX)'s Free Cash Flow (FCF) for the period is -19.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of IMUX?

    The latest valuation data shows Immunic, inc. (IMUX) has a Price-To-Earnings (PE) ratio of -1.27 and a Price/Earnings-To-Growth (PEG) ratio of 0.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.